TUM scientists develop molecules that could pave way for new treatments to fight Alzheimer's, diabetes

NewsGuard 100/100 Score

When proteins change their structure and clump together, formation of amyloid fibrils and plaques may occur. Such 'misfolding' and 'protein aggregation' processes damage cells and cause diseases such as Alzheimer's and type 2 diabetes. A team of scientists from the Technical University of Munich (TUM) headed by Professor Aphrodite Kapurniotu have now developed molecules that suppress protein aggregation and could pave the way for new treatments to combat Alzheimer's, type 2 diabetes and other cell-degenerative diseases.

The scientists designed and studied 16 different peptide molecules in order to find out which of them are able to impede the 'clumping' of the proteins amyloid beta (Aß) and islet amyloid polypeptide (IAPP), which are associated with Alzheimer's and type 2 diabetes.

The molecules were designed on the basis of scientific work that shows that the Aß and IAPP proteins interact with each other, and that this 'cross-amyloid interaction' suppresses their clumping. The researchers selected short sequences of the IAPP protein that correspond to the key regions involved in the interaction with the Alzheimer's protein. These "hot segments" were then chemically linked to each other by using specific peptide segments as 'linkers' in order to mimic and optimize the IAPP cross-amyloid interaction surface.

Powerful inhibitors block pathologically relevant amyloid proteins in Alzheimer's and diabetes

The work performed by Professor Kapurniotu's Peptide Biochemistry team at the TUM School of Life Sciences Weihenstephan together with researchers led by Professor Bernd Reif, TUM Department of Chemistry, and Professor Gerhard Rammes at Department of Anesthesiology, TUM Klinikum Rechts der Isar, identified among the designed molecules a number of powerful inhibitors of protein clumping. Three of the new peptide molecules suppressed cytotoxic clumping of both the Alzheimer's Aß and the type 2 diabetes IAPP. Another four designed peptides displayed selective inhibition of self-association of Aß; whereas one showed selective inhibition of IAPP clumping.

The results reveal a novel class of peptide leads that block misfolding and clumping of pathologically relevant amyloid proteins in Alzheimer's disease and type 2 diabetes, which could, in principle, be suitable for the development of therapeutics. In addition, the developed inhibitor design concept might find application in designing molecules that suppress disease-related interactions of other proteins as well.


  1. Rebecca Torres Rebecca Torres United States says:

    Good. The authorities should encourage proper diet so that diabetes and obesity can be avoided.

    As long as their is no clamp down on junk food, these problems would continue. I have personally suffered from obesity due to such junk food and finally lost 22 pounds with the diet of wje diabetes and got rid of a lot of healthy problems which were caused due to it. Google for "wje diabetes" to find the diet which I used.

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
1 in 5 older Canadian adults with diabetes developed functional limitations during the pandemic